Clinical Spectrum of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Protection From Symptomatic Reinfection
暂无分享,去创建一个
E. Harris | G. Kuan | A. Gordon | Á. Balmaseda | B. Carlson | N. Sanchez | S. Ojeda | B. Lopez | Mahboob A Chowdhury | J. C. Zuniga-Moya | H. Maier | S. Saborío | F. Carrillo | M. Plazaola | C. Barilla | R. López | Matt Smith | J. Kubale | A. Gajewski | B. López | A. Balmaseda | Carlos Barilla
[1] G. Di Salvo,et al. Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers , 2021, Pediatrics.
[2] R. Hirschtick,et al. Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics , 2021, Clinical Infectious Diseases.
[3] A. Dechartres,et al. Clinical characteristics and factors associated with hospital admission or death in 43 103 adult outpatients with coronavirus disease 2019 managed with the Covidom telesurveillance solution: a prospective cohort study , 2021, Clinical Microbiology and Infection.
[4] K. Mølbak,et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study , 2021, The Lancet.
[5] David A. Drew,et al. Attributes and predictors of long COVID , 2021, Nature Medicine.
[6] R. Hirschtick,et al. Population-based estimates of post-acute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics , 2021, medRxiv.
[7] Zhengming Chen,et al. Association of Age With SARS-CoV-2 Antibody Response , 2021, JAMA network open.
[8] L. Premkumar,et al. Seroepidemiology of SARS-CoV-2 infections in an urban Nicaraguan population , 2021, medRxiv.
[9] J. Rassen,et al. Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection , 2021, JAMA internal medicine.
[10] C. Wolf,et al. Sequelae in Adults at 6 Months After COVID-19 Infection , 2021, JAMA network open.
[11] J. McKerrow,et al. First report on prevalence of SARS-CoV-2 infection among health-care workers in Nicaragua , 2021, PloS one.
[12] E. Topol,et al. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic , 2021, Annals of Internal Medicine.
[13] K. Telle,et al. Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study , 2021, Scandinavian journal of public health.
[14] H. Ashktorab,et al. A Comprehensive Analysis of COVID-19 Impact in Latin America , 2021, Research square.
[15] B. Kuehn. Africa Succeeded Against COVID-19's First Wave, but the Second Wave Brings New Challenges. , 2021, JAMA.
[16] N. Alexander,et al. Clinical features and natural history of the first 2073 suspected COVID-19 cases in the Corona São Caetano primary care programme: a prospective cohort study , 2021, BMJ Open.
[17] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[18] R. Tibshirani,et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome , 2020, Science Immunology.
[19] J. Bongaarts,et al. United Nations Department of Economic and Social Affairs, Population Division World Family Planning 2020: Highlights, United Nations Publications, 2020. 46 p. , 2020 .
[20] M. Halloran,et al. Household Transmission of SARS-CoV-2 , 2020, JAMA network open.
[21] V. F. Simões,et al. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão , 2020, Revista de saude publica.
[22] Youjie Wang,et al. Epidemiological and clinical characteristics of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare workers in Hubei Province, China , 2020, Infection Control & Hospital Epidemiology.
[23] Samuel M. Brown,et al. Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network — 13 Academic Medical Centers, April–June 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[24] T. Kuno,et al. Clinical characteristics of COVID‐19 in children: A systematic review , 2020, Pediatric pulmonology.
[25] G. Kuan,et al. Symptoms, Infection Duration, and Hemagglutinin Inhibition Antibody Response in Influenza A Infections. , 2020, The Journal of infectious diseases.
[26] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[27] N. Magnavita,et al. Symptoms in Health Care Workers during the COVID-19 Epidemic. A Cross-Sectional Survey , 2020, International journal of environmental research and public health.
[28] L. Luo,et al. Secondary Transmission of Coronavirus Disease from Presymptomatic Persons, China , 2020, Emerging infectious diseases.
[29] Jun Yuan,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[30] P. Cogo,et al. SARS-COV-2 infection in children and newborns: a systematic review , 2020, European Journal of Pediatrics.
[31] Emily L. Clarke,et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries , 2020, PloS one.
[32] F. Cheng,et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China , 2020, Clinical Microbiology and Infection.
[33] Philip L. Felgner,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, medRxiv.
[34] Kun Chen,et al. Characteristics of COVID-19 infection in Beijing , 2020, Journal of Infection.
[35] Malik Peiris,et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia , 2020, Clinical chemistry.
[36] P. K. Anand,et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020 , 2020, The Indian journal of medical research.